Menu
Baseline emissions are a record of the greenhouse gasses that have been produced in the past and were produced prior to the introduction of any strategies to reduce emissions. Baseline emissions are the reference point against which emissions reduction can be measured.
| Emission Scope | Baseline Emissions, 2023 (tonnes CO2e) | Current Emissions, 2023 (tonnes CO2e) |
| Scope 1 | 0.0000 | 0.0000 |
| Energy Purchased (Sites, Other Emissions)** | 0.0000 | 0.0000 |
| Company Cars (Company Cars, Other Emissions) | 0.0000 | 0.0000 |
| Delivery Vehicles (Delivery Vehicles, Other Emissions) | 0.0000 | 0.0000 |
| Air Conditioning / Refrigerants (Other Emissions) | 0.0000 | 0.0000 |
| Scope 2 | 0.0000 | 0.0000 |
| Electricity (Sites, Other Emissions)** | 0.0000 | 0.0000 |
| Scope 3 | 38.8205 | 38.8205 |
| Purchased Goods and Services (Sites, Other Emissions)** | 0.0000 | 0.0000 |
| Capital Goods (Other Emissions) | 0.0000 | 0.0000 |
| Fuel & Energy Related Activities (Other Emissions) | 0.0000 | 0.0000 |
| Upstream Transportation & Distribution (Freighting Goods (Upstream), Other Emissions) | 0.0000 | 0.0000 |
| Waste Generated in Operations (Waste Disposal, Other Emissions) | 0.0000 | 0.0000 |
| Business Travel (Hotels, Air Travel, Public Transport & Hire Cars, Employee Owned Vehicles, Company Cars, Other Emissions) | 36.4834 | 36.4834 |
| Employee Commuting (Home Working, Employee Commuting, Other Emissions) | 2.3371 | 2.3371 |
| Upstream Leased Assets (Other Emissions) | 0.0000 | 0.0000 |
| Downstream Transportation & Distribution (Freighting Goods (Downstream), Other Emissions) | 0.0000 | 0.0000 |
| Processing of Sold Products (Other Emissions) | 0.0000 | 0.0000 |
| Use of Sold Products (Other Emissions) | 0.0000 | 0.0000 |
| End of Life Treatment of Sold Products (Other Emissions) | 0.0000 | 0.0000 |
| Franchises (Other Emissions) | 0.0000 | 0.0000 |
| Investments (Other Emissions) | 0.0000 | 0.0000 |
| Total | 38.8205 | 38.8205 |
| ** Generated from renewable sources *includes WTT |
In order to continue our progress to achieving Net Zero, we have adopted the following carbon reduction targets. We project that carbon emissions will decrease over the next years to 3.8821 by 2045 this is a reduction of 90%
| Year | Comments |
| 2023 | Scope 1 - There are no emissions associated with Scope 1 Scope 2 - There are no emissions associated with Scope 2 Scope 3 Category 4 Upstream Transportation and Distribution - There are no emissions associated with Scope 3 Category 4 Category 5 Waste Generated in Operations - There are no emissions associated with Scope 3 Category 5 Category 9 Downstream Transportation and Distribution - There are no emissions associated with Scope 3 Category 9 |
The following environmental management measures and projects are currently in progress or have been completed since the 2023 baseline.
Target Completion Date: 31/12/2025
Objective
To calculate the business mileage done by the company and reduce
Target
To reduce business mileage emissions by 01/01/2025
Action, Improvement or Control
Increase number of virtual meetings Increase use of public transport Educate employees on maintenance of their vehicles and raise awareness on fuel efficiency. Where it is possible to influence, incentivise the use of hybrid or electric vehicles.
Target Completion Date: 31/12/2025
Objective
The business aims to reduce work-related air travel by implementing better meeting and travel options, whilst ensuring flights are taken only when essential. This approach will reduce the environmental impact.
Target
Reduce flight travel by 2025 calculation date.
Action, Improvement or Control
Implement a travel hierarchy framework that requires justification for air travel, focusing on remote collaboration tools and promoting train travel for domestic journeys where feasible.
Target Completion Date: 31/12/2025
Objective
As operations increase ensure that all required data is collected throughout the year
Target
Capture of critical operational data points across all business processes and activities required for Carbon Reduction Plan on a continuous basis throughout the year.
Action, Improvement or Control
Implement a standardised data collection protocol with checkpoints and validation steps at key operational stages, supported by regular audits and staff training.
This carbon reduction plan has been completed in accordance with PPN 06/21 and the associated guidance and reporting standard for Carbon Reduction Plans.
Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHC Reporting Protocol corporate standard1and uses the appropriate Government emission conversion factors for greenhouse gas company reporting2.
Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard3.
This Carbon Reduction Plan has been reviewed and signed off by the board of directors (or equivalent management body).
The methodology used to calculate the organisation’s greenhouse gas emissions in this report is based on:
https://www.gov.uk/government/collections/government-conversion-factors-for-company-reporting
https://ghgprotocol.org/corporate-standard
https://www.gov.uk/government/collections/government-conversion-factors-for-company-reporting
https://ghgprotocol.org/standards/scope-3-standard
HeartFlow Analysis is consisted of four main functions; FFRCT, Planner, Roadmap, and Plaque. All four functions are cleared for clinical use in the United States, Bahrain, Israel, and United Arab Emirates. Only FFRCT and Planner functions are cleared cleared for clinical use in Europe, United Kingdom, Australia, Canada, and Japan. Please see HeartFlow Analysis Indications for Use and Instructions for Use for more information.
© 2024 HeartFlow, Inc. | HeartFlow and the HeartFlow logo are registered trademarks of HeartFlow, Inc. Additionally, RoadMap is claimed as a trademark of HeartFlow, Inc. www.heartflow.com | 331 E Evelyn Ave, Mountain View, CA 94041
*Required fields
If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.
*Required fields
オンライン提出フォームから研究助成金を申請してください。
HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用することを目的としています。
ハートフロー分析に関する追加の適応情報については、次のサイトをご覧ください。www.heartflow.com/indications.
さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.
The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.
For additional indication information about the HeartFlow Analysis, please visit www.heartflow.com/indications.
If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.Please use our online submission form on the Clinical Research Page to apply for research grants.
Thank you for your interest!
Executive Vice President and Chief Medical Officer
Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.
He received his A.B. from Harvard College and his M.D. from Harvard Medical School.
本情報は日本国内の医療関係者を対象とした情報提供サイトです。
一般の方に対する情報提供を目的としたものではございません。
あなたは医療関係者ですか？